Citations

Clear

164 citation(s) found for "Jenkins, Sarah".

Effect of Active Workstations on Neurocognitive Performance and Typing Skills: A Randomized Clinical Trial
Medina‐Inojosa, José R. , Ibarra, Miguel A. Gomez, Medina‐Inojosa, Betsy J. , Supervía, Marta , Jenkins, Sarah M. , Johnson, Lynne L. , Moscoso, Nathalie P Suárez , Bonikowske, Amanda R. , Somers, Virend K. , López-Jiménez, Francisco , Gomez Ibarra, Miguel A, Johnson, Lynne, Suarez, Nathalie P , Bonikowske, Amanda , Somers, Virend K. , Lopez-Jimenez, Francisco , Medina-Inojosa, José R , Medina-Inojosa, Betsy , Johnson, Lynne

Mayo Clinic

Journal of the American Heart Association | April 4, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.123.031228 | PMID 38572691 Get It

Background Extended sedentary behavior is a risk factor for chronic disease and mortality, even among those who exercise regularly. Given the time constraints of incorporating physical activity into daily schedules, and the high likelihood of sitting during office work, this environment may serve as a potentially feasible setting for interventions to reduce sedentary behavior. Methods and Results A randomized cross‐over clinical trial was conducted at an employee wellness center. Four office settings were evaluated on 4 consecutive days: stationary or sitting station on day 1 (referent), and 3 subsequent active workstations (standing, walking, or stepper) in randomized order. Neurocognitive function (Selective Attention, Grammatical Reasoning, Odd One Out, Object Reasoning, Visuospatial Intelligence, Limited‐Hold Memory, Paired Associates Learning, and Digit Span) and fine motor skills (typing speed and accuracy) were tested using validated tools. Average scores were compared among stations using linear regression with generalized estimating equations to adjust standard errors. Bonferroni method adjusted for multiple comparisons. Healthy subjects were enrolled (n=44), 28 (64%) women, mean±SD age 35±11 years, weight 75.5±17.1 kg, height 168.5±10.0 cm, and body mass index 26.5±5.2 kg/m 2 . When comparing active stations to sitting, neurocognitive test either improved or remained unchanged, while typing speed decreased without affecting typing errors. Overall results improved after day 1, suggesting habituation. We observed no major differences across active stations, except decrease in average typing speed 42.5 versus 39.7 words per minute with standing versus stepping ( P =0.003). Conclusions Active workstations improved cognitive performance, suggesting that these workstations can help decrease sedentary time without work performance impairment. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06240286.
NAB2::STAT6 fusions and genome‐wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors
Eschbacher, Kathryn L. , Tran, Quynh T. , Moskalev, Evgeny A. , Jenkins, Sarah M. , Fritchie, Karen , Stoehr, Robert , Caron, Alissa, Link, Michael J., Brown, Paul D. , Guajardo, Andrew, Wu, Ashley, Louis, David N. , Kaplan, Alexander , Ferrarese, Fabio, Raleigh, David R. , Nguyen, Minh , Gross, John , Vega, Jose Velazquez, Haller, Florian , Louis, David N , Giannini, Caterina , Link, Michael J. , Brat, Daniel J. , Santagata, Sandro , Brastianos, Priscilla K. , Alexander, Brian M. , Rossi, Sabrina , Vega, José E. Velázquez , Rodríguez, Fausto J. , Perry, Arie , Martinez‐Lage, Maria , Orr, Brent A. , Giannini, Caterina

Mayo Clinic

Brain Pathology | March 25, 2024 | Volume: 34 | Issue: 6 | Pages: No page available

10.1111/bpa.13256 | PMID 38523251 Get It

AbstractMeningeal solitary fibrous tumors (SFT) are rare and have a high frequency of local recurrence and distant metastasis. In a cohort of 126 patients (57 female, 69 male; mean age at surgery 53.0 years) with pathologically confirmed meningeal SFTs with extended clinical follow‐up (median 9.9 years; range 15 days–43 years), we performed extensive molecular characterization including genome‐wide DNA methylation profiling (n = 80) and targeted TERT promoter mutation testing (n = 98). Associations were examined with NAB2::STAT6 fusion status (n = 101 cases; 51 = ex5‐7::ex16‐17, 26 = ex4::ex2‐3; 12 = ex2‐3::exANY/other and 12 = no fusion) and placed in the context of 2021 Central Nervous System (CNS) WHO grade. NAB2::STAT6 fusion breakpoints (fusion type) were significantly associated with metastasis‐free survival (MFS) (p = 0.03) and, on multivariate analysis, disease‐specific survival (DSS) when adjusting for CNS WHO grade (p = 0.03). DNA methylation profiling revealed three distinct clusters: Cluster 1 (n = 38), Cluster 2 (n = 22), and Cluster 3 (n = 20). Methylation clusters were significantly associated with fusion type (p < 0.001), with Cluster 2 harboring ex4::ex2‐3 fusion in 16 (of 20; 80.0%), nearly all TERT promoter mutations (7 of 8; 87.5%), and predominantly an “SFT” histologic phenotype (15 of 22; 68.2%). Clusters 1 and 3 were less distinct, both dominated by tumors having ex5‐7::ex16‐17 fusion (respectively, 25 of 33; 75.8%, and 12 of 18; 66.7%) and with variable histological phenotypes. Methylation clusters were significantly associated with MFS (p = 0.027), but not overall survival (OS). In summary, NAB2::STAT6 fusion type was significantly associated with MFS and DSS, suggesting that tumors with an ex5::ex16‐17 fusion may have inferior patient outcomes. Methylation clusters were significantly associated with fusion type, TERT promoter mutation status, histologic phenotype, and MFS.
Ki-67 Proliferation Index Is Associated With Tumor Grade and Survival in Pleural Epithelioid Mesotheliomas
Galeano, Belinda, Smith, Caleb J. , Yi, Eunhee S. , Roden, Anja C. , Jenkins, Sarah M. , Capelle, Jenna, Kittle-Francis, Mary, Aubry, Marie Christine, Mansfield, Aaron S.

Mayo Clinic

American Journal of Surgical Pathology | February 19, 2024 | Volume: 48 | Issue: 5 | Pages: 615-622

10.1097/pas.0000000000002196 | PMID 38369761 Get It

Pleural epithelioid mesothelioma (PEM) is divided into low and high grades based on nuclear atypia, mitoses, and necrosis in the tumor. Assessing mitoses and nuclear atypia tend to be labor-intensive with limited reproducibility. Ki-67 proliferation index was shown to be a prognostic factor in PEM, but its performance has not been directly correlated with tumor grade or mitotic score. This study evaluated the potential of Ki-67 index as a surrogate of tumor grade. We also compared the predictability of mitoses and Ki-67 index for overall survival (OS). Ninety-six PEM samples from 85 patients were identified from the surgical pathology file during 2000-2021 at our institution, and all glass slides were reviewed by 2 pulmonary pathologists to confirm the diagnosis and assign the tumor grade. Digital image analysis (DIA) was done for Ki-67 index. The agreement on tumor grading between 2 reviewers was moderate (kappa value = 0.47). The correlation between mitotic count (average count by 2 reviewers) and Ki-67 index was 0.65. The areas under the curve for predicting tumor grade by mitotic score and Ki-67 index were 0.84 and 0.74 (reviewer 1) and 0.85 and 0.81 (reviewer 2), respectively. High Ki-67 index and mitoses were significantly associated with poor OS (P=0.03 and 0.0005, using 30% and 10/2 mm2 as cutoffs, respectively). In conclusion, Ki-67 index by DIA was associated with tumor grade as well as mitotic count, and its predictability for OS was comparable to that of mitotic score, thus being a potential surrogate for tumor grade.
Elevated LGI1-IgG CSF index predicts worse neurological outcome (P1.397)
Ζεκερίδου, Αναστασία , Gadoth, Avi , Thoreson, Colton J., Majed, Masoud , Jenkins, Sarah M. , Lennon, Vanda A. , Klein, Christopher J. , Flanagan, Eoin P. , McKeon, Andrew , Pittock, Sean J.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p1.397 Get It

AQP4-IgG Assays Comparison in Laboratory Clinical Serivce (S63.004)
Fryer, James P., Lennon, Vanda A. , Jenkins, Sarah M. , Clardy, Stacey , Horta, Erika , Jedynak, E.A., Lucchinetti, Claudia F. , Shuster, Elizabeth A., Weinshenker, Brian, Wingerchuk, Dean M. , Clardy, Stacey L , Pittock, Sean J. , McKeon, Andrew

Mayo Clinic

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.s63.004 Get It

A Mathematical Analysis of Neural Autoantibody Clusters Encountered in Sera of 78,889 Patients Undergoing Comprehensive Paraneoplastic Autoantibody Evaluation (S29.006)
Horta, Erika , Jenkins, Sarah M. , Lennon, Vanda A. , Smith, Carin Y. , McKeon, Andrew , Pittock, Sean J.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.s29.006 Get It

A Systematic Clinico-Serologic Study of Recurrent Longitudinally Extensive Transverse Myelitis (rTM) and Comparison with NMO (P02.141)
Jiao, Yujuan , Fryer, James P., Lennon, Vanda A. , Jenkins, Sarah M. , Costanzi, Chiara, Quek, Amy May Lin, Weinshenker, Brian, Wingerchuk, Dean M. , Shuster, Elizabeth A., Lucchinetti, Claudia F. , McKeon, Andrew , Smith, Carin Y. , Iorio, Raffaele , Pittock, Sean J.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.p02.141 Get It

What Is the Frequency of “Truly” AQP4-IgG-Negative NMO and Does It Differ Phenotypically from Seropositive Disease? (P02.136)
Jiao, Yujuan , Fryer, James P., Lennon, Vanda A. , Quek, Amy May Lin, Costanzi, Chiara, Jenkins, Sarah M. , Weinshenker, Brian, Wingerchuk, Dean M. , Shuster, Elizabeth A., Lucchinetti, Claudia F. , McKeon, Andrew , Iorio, Raffaele , Smith, Carin Y. , Pittock, Sean J.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.p02.136 Get It

Complementary and alternative medicine in an outpatient pediatric neurology clinic: Prevalence of use and attitudes toward CAM and prescription medications (S35.009)
Youssef, Paul E., Jenkins, Sarah , Harris, Ann, Kotagal, Suresh , Kenney‐Jung, Daniel , Jenkins, Sarah

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.s35.009 Get It

Abstract C126: Communicating breast cancer risk to Spanish-speaking Hispanic women
Tapia, Jhenitza P. Raygoza, Jenkins, Sarah M. , Gonzalez, Crystal, Hernandez, Valentina, Vachon, Celine M. , Ridgeway, Jennifer L. , Norman, Aaron D. , Patel, Bhavika , Vachon, Celine M. , Austin, Jessica D.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 1, 2023 | Volume: 32 | Issue: 12_Supplement | Pages: C126-C126

10.1158/1538-7755.disp23-c126 Get It

Abstract INTRODUCTION Disparities in breast cancer (BC) screening are observed between Hispanic and non-Hispanic White women and stronger amongst Hispanic women with under- and uninsured statuses.1-2 Risk-based screening has been recommended by professional societies, including American Cancer Society, starting at age 30 and may be an important strategy for reducing disparities.3 The purpose of the study was to characterize whether women had been told their personal risk of BC and to identify differences in characteristics of patients informed of their personal risk. METHODS This is a cross-sectional analysis of data from a supplemental self-reported survey to an NIH-funded randomized trial conducted at a large Federally Qualified Health Center (FQHC) in Arizona (R01 MD09682-05). The survey was sent to a randomized 600 of the 1,356 participants. Between November 2022 and April 2023, 177 women completed the survey (response rate 29.5%). Participants were asked if a doctor or other healthcare provider had ever talked to them about their personal risk for BC. Differences between those who recalled being told their personal risk for BC and those who did not were assessed using Fisher exact test. RESULTS Overall, 66.3% were 50 years or older, 81.8% who speak primarily Spanish, and 64.8% of respondents had less than a high school education. Also, 22.4% reported a family history of BC, 27.4% have been previously recalled for additional imaging, 10.8% have had a history of prior breast biopsy, 59.9% stated having a regular provider, and 53.1% were found to have dense breast category C or D at screening visit. 40% did not report having a regular doctor although all participants received care at an FQHC. 30.5% of respondents stated that a healthcare professional had ever talked to them about their personal risk for BC. There was a trend toward women with a main doctor being more likely to recall being told their personal risk for BC as compared to those without a main doctor (38.5% vs 22.5%, p=0.06). CONCLUSIONS In this cohort of primarily Spanish-speaking Hispanic women who have had mammography screening and written report of their breast density, about a third of respondents recall being informed of their personal BC risk. These observations need to be confirmed in a larger population with greater response rate, but these results suggest that there is a cohort of patients who need different approaches for conveying risk. REFERENCES 1. Jadav, S., Rajan, S. S., Abughosh, S., & Sansgiry, S. S. (2015). The Role of Socioeconomic Status and Health Care Access in Breast Cancer Screening Compliance Among Hispanics. Journal of Public Health Management and Practice, 21(5), 467–476. https://www.jstor.org/stable/48517175 2. American Cancer Society. (2017). Breast cancer facts & figures 2017-2018. Atlanta, GA: American Cancer Society, Inc. 3. ACS Breast Cancer Screening Guidelines. (2022, January 14). https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.htm Citation Format: Jhenitza P. Raygoza Tapia, Sarah M. Jenkins, Jennifer L. Ridgeway, Aaron D. Norman, Crystal R. Gonzalez, Valentina Hernandez, Bhavika K. Patel, Celine M. Vachon, Jessica D. Austin. Communicating breast cancer risk to Spanish-speaking Hispanic women [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C126.